Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of GLP1 receptor rs6923761 and rs761387 genetic variants on oral semaglutide response in patients with type 2 diabetes.

Acta diabetologica - 1 Feb 2026

Candido Riccardo, Toffoli Barbara, Baccichetto Gabriele, Marchese Francesca, Carpenè Silvia, Gaiotti Sara, Fabris Bruno, Bernardi Stella

Abstract excerpt

AIMS: Glucagon-like peptide-1 receptor (GLP-1R) has become one of the most promising ligand-receptor systems to target for type 2 diabetes mellitus (T2DM) treatment. Over the last two decades, several GLP-1 receptor agonists (GLP-1RAs) have been developed and semaglutide is the first and only GLP-1RA available as an oral formulation. GLP1R single nucleotide polymorphisms may affect GLP-1R response to oral...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Blood Glucose

Share to Diabetes Mellitus, Type 2

Share to Glucagon-Like Peptide-1 Receptor

Share to Glycated Hemoglobin

Share to Hypoglycemic Agents

Share to Polymorphism, Single Nucleotide

Source

Open in PubMed Open full text

Identifiers

PMID: 41307691
DOI: 10.1007/s00592-025-02626-9
PMCID: PMC12957030

Genes

GLP1R
ACR
DBP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of GLP1 receptor rs6923761 and rs761387 genetic variants on oral semaglutide response in patients with type 2 diabetes.PMID 41307691Read ↗

GLP1R and OCT1 variants modulate semaglutide and metformin response in type 2 diabetes.Semantic proximity Read ↗

Pharmacogenomics of GLP-1 Receptor Agonists: Precision Medicine in the Age of Ozempic and MounjaroSemantic proximity Read ↗

GLP1R Variants and Polygenic Risk Underlie Heterogeneous Response to GLP-1 Receptor Agonists in Type 2 DiabetesSemantic proximity Read ↗

Pharmacogenomics of GLP-1 Receptor Agonists: A genome wide analysis of observational data and large randomized controlled trialsSemantic proximity Read ↗

Genetic variations in GLP-1R: Impact on diabetes and obesity therapeutics.Semantic proximity Read ↗

A GLP1R gene variant and sex influence the response to semaglutide treatment in patients with severe obesitySemantic proximity Read ↗

Influence of BMI-associated genetic variants and metabolic risk factors on weight loss with semaglutide: a longitudinal clinico-genomic cohort studySemantic proximity Read ↗

GLP Medications and Severe Post-COVID-19 Outcomes Among Individuals with Type 2 Diabetes MellitusSemantic proximity Read ↗

Genetic variants associated with glycemic response to treatment with dipeptidylpeptidase 4 inhibitors.Semantic proximity Read ↗

Long-Term Efficacy and Safety of GLP-1R Agonist and SGLT2 Inhibitor Therapy in the General Population: A 2x2 Factorial Mendelian Randomization StudySemantic proximity Read ↗

Genetic predictors of GLP1 receptor agonist weight loss and side effects.Semantic proximity Read ↗

Acute pharmacodynamic responses to exenatide: Drug-induced increases in insulin secretion and glucose effectivenessSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.